This inventor holds 2 USPTO granted patents and 6 published patent applications. Top assignees: Cincinnati Children's Hospital Medical Center, Kurome Therapeutics, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2026.
Company Filing History:
2 out of 429 
2 out of 2 
2 out of 3,688 
Years Active: 2026
Title: Scott Bryan Hoyt: Innovator in Cancer Treatment
Introduction
Scott Bryan Hoyt is a notable inventor based in Arlington, VA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific diseases. His work focuses on innovative solutions for treating hematopoietic cancers and related conditions.
Latest Patents
Scott Bryan Hoyt holds a patent for "Multi-cyclic IRAK and FLT3 inhibiting compounds and uses thereof." This patent includes inventive compounds and pharmaceutical compositions that inhibit IRAK and/or FLT3, which can be utilized in treating various diseases. The patent outlines methods for administering these compounds to treat conditions such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Additionally, it discusses the potential for combining these innovative compounds with other cancer therapies to enhance treatment efficacy.
Career Highlights
Throughout his career, Scott has worked with esteemed organizations, including Cincinnati Children's Hospital Medical Center and the United States Department of Health and Human Services. His experience in these institutions has allowed him to contribute to significant advancements in medical research and treatment methodologies.
Collaborations
Scott has collaborated with notable colleagues, including Chris James Finocchio and Daniel T Starczynowski. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of cancer research.
Conclusion
Scott Bryan Hoyt is a dedicated inventor whose work in developing IRAK and FLT3 inhibiting compounds represents a significant advancement in cancer treatment. His contributions to the pharmaceutical industry continue to impact the lives of many patients facing serious health challenges.